The following representatives of BioInvent International AB’s shareholders will be members of the Nomination Committee for the Annual
Laura Feinleib , appointed byRedmile Group, LLC ,Erik Esveld , appointed by vanHerk Investments B.V. ,- Dr.
Ivo Staijen appointed byHBM Healthcare Investments Ltd , and Leonard Kruimer , Chairman of the Board.
The Nomination Committee shall prepare proposals for the Annual General Meeting in 2023 regarding Chairman of the General Meeting, Chairman of the Board and other Board members, board remuneration shared among the Chairman and other Board members and possible compensation for committee work.
The Annual General Meeting will be held on
Proposals to the Nomination Committee can be sent to
About
The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company's fully integrated manufacturing unit. More information is available at www.bioinvent.com. Follow on Twitter: @BioInvent.
For further information, please contact:
Senior Director Investor Relations
+46 (0)46 286 85 50
cecilia.hofvander@bioinvent.com
Co. Reg. No. Org nr: 556537-7263
Visiting address: Ideongatan 1
Mailing address: 223 70 LUND
Phone: +46 (0)46 286 85 50
www.bioinvent.com
© Modular Finance, source